Raloxifene has been demonstrated to reduce PDAC cells by disturbing the expression of ERβ and inhibiting the IL-6/gp130/STAT3 signaling pathway, indicating ERβ may carcinogenic role in pancreatic cancer (149). The gene discussed is ESR2; the disease is familial pancreatic carcinoma.